- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02579005
Radio-Immuno-Modulation in Lung Cancer (RIM)
Radio-Immuno-Modulation for Advanced Lung Cancer: a Pilot Study Evaluating Tolerance and Immune Responses
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Metastatic lung cancer remains incurable despite numerous studies and treatments tried, including chemotherapy and, more recently, targeted therapies.
Cancer can escape immune surveillance through different mechanisms: low levels of tumor associated antigens (TAA), regulatory T cells, and immunosuppressive cytokines. Non-cytolytic doses of radiation have been shown to reverse some of these pathways in experimental models. It up-regulated the density of the MHC molecules presenting TAA and increased the T cell infiltration of the tumor (1). Patients with lymphoma, liver or prostate cancer were treated with radiotherapy combined with immunotherapy, in the form of a TLR9 agonist, autologous dendritic cells or a prostate-specific antigen vaccine (2, 3, 4). These trials have shown an induction of T cell reactivity against TAA. Another form of immunotherapy, used for patients with refractory hematologic malignancies is allogeneic hematopoietic stem cell transplantation (HSCT) (5). Its success has relied on cell infusions from a donor, demonstrating the immunologic control sustained by allogeneic cells (6).
The approach investigated in this study uses the immune cells from a donor to induce a tumor destruction reaction. This will be amplified by the immunological effects of radiotherapy. Many oncogenes are present in lung cancers and low-dose radiation increases their expression on the surface of the tumor cell. In addition, radiation has the property to stimulate the production of inflammatory cytokines and chemokines in the irradiated site. Finally, the donor's immune cells shall respond physiologically by migrating to the site of inflammation. This will trigger an immune reaction directed against the abnormal cancer cells.
A total of 24 patients are expected to be recruited over the study period, estimated to be 3 years. The allogeneic cells will be obtained from one of two possible donor types. For patients having a living donor, the immune cells will be harvested through a collection procedure called apheresis. The living donor should be a sibling with 3/6 or less HLA compatibility with the patient, at the A, B and DRB1 loci. For patients who do not have such a living donor, allogeneic cells from a cryopreserved umbilical cord blood (UCB) unit will be used.
The treatment course will be the following: low-dose radiotherapy will be delivered to a single tumor site, which could be either the primary tumor or one of its metastases. Low-dose cyclophosphamide will be given to decrease regulatory T cell activity and increase anti-tumor responses. Allogeneic immune cells will be administered thereafter, according to the treatment arm the patient has been assigned.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H4J 1C5
- Hopital Sacre-Coeur
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Advanced lung cancer documented by a histo-pathological analysis;
- Patients who received at least one line of anti neoplastic therapy;
- Presence of at least one tumor mass >1 cm and not previously irradiated;
- Metastases situated in one of the following sites: lung, skeleton, lymph nodes or soft tissue;
- Presence of at least one not previously irradiated metastasis;
- Life expectancy greater than 3 months;
- ECOG performance status ≤ 2.
Exclusion criteria:
- Second active cancer necessitating treatment;
- History of autoimmune disease;
- Patients dependent on immunosuppressive medications, including corticosteroids;
- Decreased diffusion capacity below 40%, if radiation planned to a lung metastasis;
- Patients needing urgent radiotherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients with a living donor
Radiation + PBMC
|
The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n.
The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3.
Cyclophosphamide, 250 mg/m2 will be given on Day -2.
Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4.
PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered.
The infused volume will be adjusted to contain this T cell dose.
|
Experimental: Patients with a UCB donor
Radiation + UCB
|
The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n.
The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight.
The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3.
Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-related adverse events
Time Frame: Up to 6 months
|
Evaluation by follow-up clinic visits, including medical questionnaire, physical exam & blood tests: complete blood count, electrolytes, renal & liver function tests.
AE will be graded using National Cancer Institute's Common Toxicity Criteria version 3 (7).
Evaluations will take place twice a week for the first 2 weeks, weekly for 2 weeks, every 2 weeks for 2 months & every month for 3 months.
It is anticipated that a maximum of 1 of 6 patients will have grade 3 side effects, including nausea, diarrhea, dyspnea, cough, fever, rash.
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immune responses - T cell infiltration
Time Frame: Up to 1 month
|
Assessment using biopsies done before & 1-2 weeks after treatment.
The block slides will be stained with CD3, CD4, CD8 & PDL-1 antibodies.
T cell density will be expressed as the number of CD4+ and CD8+ cells to tumor cell ratio.
The degree of T cell infiltration of the tumors will be assessed by comparing these ratios between pre & post treatment samples.
|
Up to 1 month
|
Immune responses - Tumor cell phenotype
Time Frame: Up to 1 month
|
Assessment using biopsies done before & 1-2 weeks after treatment.
Flow cytometry will be used to assess the following tumor markers: HLA, Fas, ICAM-1, PDL-1.
The changes in tumor cell phenotypes will be assessed by comparing the mean fluorescence intensity of the above markers between pre & post treatment samples.
The PDL-1 tumor cell expression will also be compared on the block slides between pre & post treatment samples.
|
Up to 1 month
|
Immune responses - tumor infiltrating T cell phenotype
Time Frame: Up to 1 month
|
Assessment using biopsies done before & 1-2 weeks after treatment.
Flow cytometry will be used to assess the following markers on tumor infiltrating T cells: CD3, CD4, CD8, CD25 & Foxp3.
The nature and magnitude of T cell infiltration will be assessed by comparing the frequencies of these T cell subsets between pre & post treatment samples.
|
Up to 1 month
|
Immune responses - origin of tumor infiltrating T cells
Time Frame: Up to 1 month
|
Assessment using biopsies done 1-2 weeks after treatment.
Single cell suspensions will be stained with the following markers for tumor infiltrating T cells: CD3, CD4 and CD8.
CD4+ and CD8+ T cells will be isolated by fluorescence-activated cell sorting.
Their origin (patient vs donor) will be determined by a chimerism assay.
The frequencies of donor-derived cells will be determined by PCR quantification of patient and donor specific VNTR bands.
|
Up to 1 month
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Razvan B Diaconescu, MD, CIUSSS du Nord-de-l'Île-de-Montréal - Hôpital du Sacré-Cœur de Montréal
Publications and helpful links
General Publications
- Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park). 2008 Aug;22(9):1064-70; discussion 1075, 1080-1, 1084.
- Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010 Oct 1;28(28):4324-32. doi: 10.1200/JCO.2010.28.9793. Epub 2010 Aug 9.
- Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother. 2005 Mar-Apr;28(2):129-35. doi: 10.1097/01.cji.0000154248.74383.5e.
- Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005 May 1;11(9):3353-62. doi: 10.1158/1078-0432.CCR-04-2062. Erratum In: Clin Cancer Res. 2006 Jan 1;12(1):322.
- Diaconescu R, Storb R. Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care. J Cancer Res Clin Oncol. 2005 Jan;131(1):1-13. doi: 10.1007/s00432-004-0611-6. Epub 2004 Sep 28.
- Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE, Chauncey TR, Flowers ME, Mielcarek M, Maloney DG, Storb R. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005 Mar 20;23(9):1993-2003. doi: 10.1200/JCO.2005.08.136.
- 7. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD. National Cancer Insitute, 2006. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-634
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Patients with a living donor
-
Akdeniz UniversityCompletedNeurologic Manifestations | Delirium | Donor Site Complication | Uremic EncephalopathyTurkey
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrolling by invitationKidney DiseasesUnited States
-
Georgia Southern UniversityCompletedDevelopmental Disabilities | Health Education | Community Health Services | Health Services for Persons With DisabilitiesUnited States
-
Virginia Commonwealth UniversityAgency for Healthcare Research and Quality (AHRQ)CompletedKidney Transplant CandidatesUnited States
-
Kyoto University, Graduate School of MedicineMinistry of Health, Labour and Welfare, JapanCompleted
-
Jena University HospitalUniversity Hospital TuebingenRecruitingColorectal Cancer Metastatic | Liver MetastasesGermany
-
Alaa Mstafa Hassan SewefyAin Shams UniversityCompleted
-
Maidstone & Tunbridge Wells NHS TrustRecruiting
-
Samsung Medical CenterCompletedDeceased Donor Kidney Transplantation | Living Donor Kidney TransplantationKorea, Republic of
-
University Hospital, GrenobleGroupe Hospitalier Mutualiste de Grenoble; Centre Hospitalier Annecy Genevois; Centre Hospitalier Metropole Savoie and other collaboratorsRecruitingCoronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry (3CRegistry)Hypertrophic | Ischemic | Restrictive Cardiomyopathy | Dilated CardiomyopathiesFrance